STOCK TITAN

Quantum-Si’s Customers and Researchers to Showcase Next-Generation Protein Sequencing™ at AGBT 2025

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Very Positive)
Tags

BRANFORD, Conn.--(BUSINESS WIRE)-- Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI” or the “Company”), The Protein Sequencing Company, and several distinguished researchers will be presenting new research and applications at the 2025 Advances in Genome Biology and Technology (AGBT) General Meeting February 23-26th.

Quantum-Si, the pioneer in Next-Generation Protein Sequencing (NGPS™) will feature groundbreaking research through one company-led poster and two customer-led posters highlighting the transformative capabilities of NGPS in multi-omics research and drug discovery.

Scientific Posters Highlighting NGPS Innovation

Beyond the genome: Advancing our understanding of the proteome with Next-Generation Protein Sequencing

  • Presenter: Meredith Carpenter, Ph.D., Head of Scientific Affairs, Quantum-Si
  • Introduces how NGPS offers an integrated understanding of cellular processes by detecting changes at the protein level (such as post-translational modifications, or PTMs) that cannot be captured by genomics data alone.
  • February 25th, Poster 412

Integrating long-read RNAseq and Next-Generation Protein Sequencing™ to explore proteoform variability

  • Presenter: Gloria Sheynkman, Ph.D., Assistant Professor, University of Virginia
  • Demonstrates the integration of long-read RNA sequencing to capture transcript isoforms, combined with the benchtop instrument Platinum™ to produce single-molecule peptide sequencing data.
  • February 25th Poster 476

Identifying Protein Binding Partners at the Bench Using Quantum-Si

  • Presenter: Winston Timp, Ph.D., Associate Professor, BioMedical Engineering and Molecular Biology and Genetics, Johns Hopkins University
  • Demonstrates how NGPS enables direct peptide sequencing to identify protein partners regulated by genomic, epigenomic, or splicing variation, offering a rapid and cost-effective alternative to legacy technologies.
  • February 24th, Poster 465

About Quantum-Si Incorporated

Quantum-Si, The Protein Sequencing Company™, is focused on revolutionizing the growing field of proteomics. The Company’s Platinum® line of instruments enables Next-Gen Protein Sequencing™ that advances proteomic research, drug discovery, and diagnostics beyond what has been possible with existing proteomic tools. Learn more at quantum-si.com or follow us on LinkedIn or X.

Investor Contact

Jeff Keyes

Chief Financial Officer

ir@quantum-si.com



Media Contact

Katherine Atkinson

SVP, Commercial Marketing

media@quantum-si.com

Source: Quantum-Si Incorporated

FAQ

What research will be presented at AGBT 2025 featuring Quantum-Si's technology?

Three scientific posters will be presented: one by QSI on protein-level changes detection, one by University of Virginia on RNA sequencing integration, and one by Johns Hopkins University on protein partner identification using NGPS technology.

How is Quantum-Si's Platinum™ instrument being used in academic research?

The Platinum™ instrument is being used for single-molecule peptide sequencing and is being integrated with long-read RNA sequencing to explore proteoform variability.

What advantages does QSI's Next-Generation Protein Sequencing offer over existing technologies?

NGPS offers detection of post-translational modifications, provides integrated understanding of cellular processes, and presents a rapid, cost-effective alternative to legacy technologies for identifying protein binding partners.

Which academic institutions are presenting research using Quantum-Si's technology at AGBT 2025?

The University of Virginia and Johns Hopkins University will be presenting research using Quantum-Si's technology at AGBT 2025.
Quantum-Si Incorporated

NASDAQ:QSI

QSI Rankings

QSI Latest News

QSI Stock Data

225.27M
139.49M
14.83%
29.05%
9.65%
Medical Devices
Measuring & Controlling Devices, Nec
Link
United States
BRANFORD